title: Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group.
abstract: Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2'-deoxycoformycin, dCF) 4mg/m2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.
authors.affiliation: Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
authors.forename: R
authors.initials: R
authors.lastname: Sorio
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
authors.forename: T H
authors.initials: TH
authors.lastname: Cerny
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.forename: J F
authors.initials: JF
authors.lastname: Smyth
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000532:radiotherapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D015649:Pentostatin